[go: up one dir, main page]

ATE303795T1 - In biologisch abbaubare polymere eingekapselter serotoninrezeptor-antagonist und deren herstellungsverfahren - Google Patents

In biologisch abbaubare polymere eingekapselter serotoninrezeptor-antagonist und deren herstellungsverfahren

Info

Publication number
ATE303795T1
ATE303795T1 AT99960556T AT99960556T ATE303795T1 AT E303795 T1 ATE303795 T1 AT E303795T1 AT 99960556 T AT99960556 T AT 99960556T AT 99960556 T AT99960556 T AT 99960556T AT E303795 T1 ATE303795 T1 AT E303795T1
Authority
AT
Austria
Prior art keywords
encapsuled
production method
receptor antagonist
biodegradable polymers
serotonine receptor
Prior art date
Application number
AT99960556T
Other languages
English (en)
Inventor
Rachel S Kohn
Stephen J Hanley
Stephen J Comiskey
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE303795T1 publication Critical patent/ATE303795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
AT99960556T 1998-12-16 1999-11-22 In biologisch abbaubare polymere eingekapselter serotoninrezeptor-antagonist und deren herstellungsverfahren ATE303795T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16
PCT/US1999/027705 WO2000035423A1 (en) 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same

Publications (1)

Publication Number Publication Date
ATE303795T1 true ATE303795T1 (de) 2005-09-15

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960556T ATE303795T1 (de) 1998-12-16 1999-11-22 In biologisch abbaubare polymere eingekapselter serotoninrezeptor-antagonist und deren herstellungsverfahren

Country Status (35)

Country Link
EP (1) EP1140026B1 (de)
JP (1) JP4759141B2 (de)
KR (1) KR100707710B1 (de)
CN (1) CN1195497C (de)
AP (1) AP1769A (de)
AR (1) AR021652A1 (de)
AT (1) ATE303795T1 (de)
AU (1) AU770673B2 (de)
BG (1) BG65500B1 (de)
BR (1) BR9916276A (de)
CA (1) CA2355077C (de)
CR (1) CR6424A (de)
CZ (1) CZ301947B6 (de)
DE (1) DE69927177T2 (de)
DK (1) DK1140026T3 (de)
EA (1) EA004502B1 (de)
EE (1) EE200100314A (de)
ES (1) ES2245128T3 (de)
HK (1) HK1041645B (de)
HR (1) HRP20010446A2 (de)
HU (1) HU226586B1 (de)
ID (1) ID28909A (de)
IL (2) IL143761A0 (de)
ME (2) ME00066B (de)
NO (1) NO20012981L (de)
NZ (1) NZ511962A (de)
OA (1) OA11728A (de)
PL (1) PL196822B1 (de)
RS (1) RS50123B (de)
SK (1) SK285812B6 (de)
TR (1) TR200101759T2 (de)
TW (1) TWI221418B (de)
UA (1) UA73101C2 (de)
WO (1) WO2000035423A1 (de)
ZA (1) ZA200104899B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
AU2002256694A1 (en) * 2001-03-20 2002-10-03 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
BR0209914A (pt) 2001-05-23 2004-04-06 Hexal Ag Produto homogeneizado para implantes e micropartìculas
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
EP1797871B1 (de) * 2004-09-21 2015-02-25 Shandong Luye Pharmaceutical Co., Ltd. Langwirkende formulierung mit verzögerter freisetzung mit einem dopamin-rezeptoragonist und herstellungsverfahren dafür
EP2262484B1 (de) 2008-03-11 2013-01-23 Depomed, Inc. Gastroretentive darreichungsformen mit verzögerter freisetzung mit komibinationen aus einem nichtopioiden analgetikum und einem opioiden analgetikum
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
BR112022012260A2 (pt) * 2019-12-31 2022-08-30 Wanka Tanka Ltd Formulação plástica de liberação estendida

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (de) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
EP0528978B1 (de) * 1990-05-16 2002-10-16 Southern Research Institute Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
DK0531410T3 (da) * 1990-06-01 1995-01-30 Merrell Dow Pharma (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
AU4467396A (en) * 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm

Also Published As

Publication number Publication date
HUP0105048A2 (hu) 2002-05-29
CN1195497C (zh) 2005-04-06
SK8282001A3 (en) 2001-11-06
IL143761A (en) 2006-08-01
CR6424A (es) 2004-02-26
AR021652A1 (es) 2002-07-31
ID28909A (id) 2001-07-12
WO2000035423A1 (en) 2000-06-22
NO20012981D0 (no) 2001-06-15
KR20010082359A (ko) 2001-08-29
BR9916276A (pt) 2001-09-04
WO2000035423A9 (en) 2002-08-22
MEP19408A (en) 2010-06-10
TR200101759T2 (tr) 2001-12-21
HRP20010446A2 (en) 2002-06-30
YU41401A (sh) 2003-12-31
SK285812B6 (sk) 2007-08-02
BG105591A (en) 2002-01-31
PL196822B1 (pl) 2008-02-29
CN1330536A (zh) 2002-01-09
TWI221418B (en) 2004-10-01
ME00066B (me) 2010-06-10
HK1041645B (zh) 2005-07-29
KR100707710B1 (ko) 2007-04-18
AU1742500A (en) 2000-07-03
CZ301947B6 (cs) 2010-08-11
CA2355077C (en) 2009-05-26
PL348233A1 (en) 2002-05-20
DK1140026T3 (da) 2006-01-02
AP1769A (en) 2007-08-22
EP1140026A1 (de) 2001-10-10
HUP0105048A3 (en) 2002-09-30
OA11728A (en) 2005-02-01
EE200100314A (et) 2002-08-15
ES2245128T3 (es) 2005-12-16
EA200100551A1 (ru) 2001-10-22
IL143761A0 (en) 2002-04-21
HK1041645A1 (en) 2002-07-19
EP1140026B1 (de) 2005-09-07
CA2355077A1 (en) 2000-06-22
UA73101C2 (en) 2005-06-15
NZ511962A (en) 2003-06-30
DE69927177D1 (de) 2005-10-13
EA004502B1 (ru) 2004-04-29
JP2002532408A (ja) 2002-10-02
BG65500B1 (bg) 2008-10-31
DE69927177T2 (de) 2006-06-08
HU226586B1 (en) 2009-04-28
ZA200104899B (en) 2002-09-16
NO20012981L (no) 2001-07-27
CZ20012157A3 (cs) 2001-09-12
AU770673B2 (en) 2004-02-26
AP2001002198A0 (en) 2001-09-30
RS50123B (sr) 2009-03-25
JP4759141B2 (ja) 2011-08-31

Similar Documents

Publication Publication Date Title
ATE303795T1 (de) In biologisch abbaubare polymere eingekapselter serotoninrezeptor-antagonist und deren herstellungsverfahren
DE69941340D1 (de) Vernetzte leitfähige polymerkomposit-materialen und verfahren zu deren herstellung
ID29013A (id) Ligan-ligan reseptor novel thiroid dan metode ii
DE69939221D1 (de) Mehrschichtige leiterplatte und verfahren zu deren herstellung
ATE389388T1 (de) Zusammensetzungen mit verzoegerter freisetzung und verfahren zu deren herstellung
DE69938182D1 (de) Mehrschichtige leiterplatte und verfahren zu deren herstellung
HUP0201461A2 (en) Polymer material, producing process of said material which contains weathering resistance component and its using in building industry
DE19983874T1 (de) Ionenempfindliche, in hartem Wasser dispergierbare Polymere und deren Verwendungen
DE69839716D1 (de) Leitende Polymere verwendender Festelektrolytkondensator und dessen Herstellungsverfahren
ATE277905T1 (de) 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
PL341890A1 (en) Novel derivatives of 1,2,4,5-tetrahydrobenzo[d]diazepin, method of obtaining them, pharmacological agent, method of obtaining same, application of said novel derivatives in obtaining that pharmacological agent and pllication of radioactive tracer labelled antagonist of mg1ur1 receptor
HUP0104699A3 (en) Biodegradable polymer and process for producing them
DE60013270D1 (de) Polyfluorierte epoxide und assozierte polymere und verfahren
DE69910623D1 (de) Polymer/ton nanokomposit und verfahren zu seiner herstellung
DE69942033D1 (de) Verfahren und struktur zum verbinden von batterien
DE69827144D1 (de) Neue blockpolymere und deren herstellung
FI974262A (fi) Menetelmä ja laite polymeerien valmistamiseksi
DE69633873D1 (de) Alkalische cellulase und verfahren zu deren herstellung
DE59913422D1 (de) Femfet-vorrichtung und verfahren zu deren herstellung
DE69936450D1 (de) Warenüberwachungssystem anlage und deren herstellungsverfahren
GB9820014D0 (en) Receptor antagonists and uses thereof
NO970247L (no) Aktiverte polymer partikler med en smal st°rrelsesfordeling og metode for fremstilling
EE200000297A (et) Postisortimissüsteem ja -meetod
EE200100710A (et) Meetod ja seade graanulite valmistamiseks
DE50011118D1 (de) Speicherzellenanordnung und verfahren zu deren herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140026

Country of ref document: EP

EEIH Change in the person of patent owner